A

Asymchem Laboratories Tianjin Co Ltd
SZSE:002821

Watchlist Manager
Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
Watchlist
Price: 84 CNY -5.08% Market Closed
Market Cap: 28.7B CNY
Have any thoughts about
Asymchem Laboratories Tianjin Co Ltd?
Write Note

Asymchem Laboratories Tianjin Co Ltd
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Asymchem Laboratories Tianjin Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
A
Asymchem Laboratories Tianjin Co Ltd
SZSE:002821
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Issuance of Debt
-ÂĄ19m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Issuance of Debt
ÂĄ163.2m
CAGR 3-Years
176%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Issuance of Debt
-ÂĄ16.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Issuance of Debt
ÂĄ894.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Issuance of Debt
ÂĄ208m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Asymchem Laboratories Tianjin Co Ltd
Glance View

Market Cap
31B CNY
Industry
Pharmaceuticals

Asymchem Laboratories Tianjin Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Tianjin, Tianjin and currently employs 7,126 full-time employees. The company went IPO on 2016-11-18. Asymchem Laboratories (Tian Jin) Co Ltd is a China-based company mainly engaged in the contract development manufacturing organization (CDMO) of drugs. The firm's main businesses are the process development, amplification and commercialization of chemical drugs. The firm's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The firm is also engaged in the provision of pharmaceutical formulation solutions, biosynthetic solutions and clinical solutions.

Intrinsic Value
102.05 CNY
Undervaluation 18%
Intrinsic Value
Price
A

See Also

Back to Top